Real-world evaluation of anti-VEGF therapy in diabetic macular edema: The role of macular ischemia and OCT biomarkers BOSPHORUS DME study group report no: 14.

Based on FFA before treatment, patients were divided into two groups: those with macular ischemia and those without macular ischemia.

Macular ischemia was detected in 238 eyes (23.7%).

After adjustment for baseline covariates, ischemic eyes demonstrated longitudinal BCVA improvement at months 6 and 12 despite persistently lower overall vision levels.

CMT significantly decreased over time in both groups without significant differences in anatomical response.